Can a vaccine keep TB away for good? new study tests H56:IC31
NCT ID NCT03512249
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested an experimental vaccine called H56:IC31 in 831 adults who had just finished treatment for tuberculosis (TB). The goal was to see if the vaccine could lower the chance of TB coming back. Participants were randomly assigned to get either the vaccine or a placebo, and researchers tracked how many got TB again over time.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TUBERCULOSIS, PULMONARY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
NIMR Mbeya Medical Research Centre
Mbeya, Tanzania
-
South African Tuberculosis Vaccine Initiative , Project Office, Brewelskloof Hospital , Harlem Street, Worcester
Cape Town, Western Cape, 6850, South Africa
-
Task Clinical Research Centre
Bellville, Cape Town, 7530, South Africa
-
The Aurum Institute
Klerksdorp, North West, 2570, South Africa
-
The Aurum Institute: Tembisa Clinical Research Centre
Tembisa, Gauteng, 1632, South Africa
-
University of Cape Town Lung Institute
Mowbray, Cape Town, South Africa
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New rapid test could free TB patients from isolation sooner
- New TB cocktail aims to shorten treatment
- AI stethoscope aims to cut unnecessary antibiotics in kids with cough
- Pee test could spot TB patients skipping meds
- Could aspirin or ibuprofen help beat TB faster?
- Exercise program aims to boost lung health in TB survivors